Allworth Financial LP Mirati Therapeutics, Inc. Transaction History

Allworth Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 24, 2024	BUY	$41.99 - $62.38 $1,133 - $1,684	27 Added 33.75%	107 $6,000
Q3 2023 Oct 31, 2023	BUY	$27.8 - $45.35 $2,224 - $3,628	80 New	80 $3,000
Q1 2023 Apr 18, 2023	BUY	$36.54 - $54.26 $803 - $1,193	22 New	22 $0
Q3 2022 Oct 18, 2022	SELL	$59.5 - $86.7 $8,806 - $12,831	-148 Reduced 96.1%	6 $0
Q2 2022 Jul 13, 2022	BUY	$39.16 - $88.71 $6,030 - $13,661	154 New	154 $10,000
Q4 2021 Jan 21, 2022	SELL	$132.01 - $190.29 $9,240 - $13,320	-70 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$132.13 - $177.45 $9,249 - $12,421	70 New	70 $12,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

Stay updated on Allworth Financial LP with notifications on news.